Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDM-Guided SSRI Treatment in Depression
NCT07478796Phase 4Recruiting
- Sponsor
- Poznan University of Medical Sciences
- Start
- Apr 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of fluoxetine, Escitalopram oxalate oral solution and sertraline in major depressive disorder (MDD) (3 arms), sponsored by Poznan University of Medical Sciences. Primary endpoints: Change in Depression Severity (Children's Depression Inventory) at Week 8 and Change in Depression Severity (Montgomery-Asberg Depression Rating Scale) at Week 8. Started Apr 2025; status: recruiting.
02
Drugs
fluoxetineEscitalopram oxalate oral solutionsertraline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07478796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07478796.